Clinical Trial Update: Baricitinib for Post-HSCT Persistent Thrombocytopenia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating baricitinib for persistent thrombocytopenia after allogeneic hematopoietic stem cell transplantation; currently not yet recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Persistent Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING